{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.3","upperLimit":"17.5","value":"6.4"},{"groupId":"OG001","lowerLimit":"9.1","upperLimit":"51.2","value":"26.3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"47"},{"groupId":"OG001","value":"19"}],"units":"Participants"}],"description":"Percentage of participants with a confirmed objective response rate (ORR) by blinded independent central review (BICR) assessment was analyzed and reported for both PCNSL and PTL patient populations.\n\nThis endpoint is further defined as the percentage of participants with a best overall response (BOR) of complete response (CR) or partial response (PR), based on the IPCG Criteria for PCNSL and Lugano 2014 response evaluation for PTL, divided by the number of treated participants within each cohort.","dispersionType":"95% Confidence Interval","groups":[{"description":"Nivolumab dosed to participants with relapsed/refractory Primary Central Nervous System Lymphoma (PCNSL).\n\nNivolumab 240 mg was given every 2 weeks for 8 cycles. Beginning with Cycle 9, nivolumab 480 mg was given every 4 weeks for a total therapy duration of 2 years, or until progressive disease, unacceptable toxicity, or withdrawal of consent. Nivolumab was administered as a 30-minute infusion.","id":"OG000","title":"PCNSL Cohort"},{"description":"Nivolumab dosed to participants with relapsed/refractory Primary Testicular Lymphoma (PTL).\n\nNivolumab 240 mg was given every 2 weeks for 8 cycles. Beginning with Cycle 9, nivolumab 480 mg was given every 4 weeks for a total therapy duration of 2 years, or until progressive disease, unacceptable toxicity, or withdrawal of consent. Nivolumab was administered as a 30-minute infusion.","id":"OG001","title":"PTL Cohort"}],"paramType":"NUMBER","populationDescription":"All treated PCNSL and PTL participants","reportingStatus":"POSTED","timeFrame":"Up to approximately 51 months","title":"BICR-Assessed Objective Response Rate (ORR)","type":"PRIMARY","unitOfMeasure":"Percentage of participants"}